Page last updated: 2024-12-08

fti 276

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FTI 276: a ras CAAX (C - Cys; A - aliphatic amino acid; X - Ser or Met) peptidomimetic; inhibits farnesyltransferase; FTI-277 is the methyl ester derivative of FTI-276 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID395754
CHEMBL ID54044
CHEBI ID94119
SCHEMBL ID2722114
MeSH IDM0357283

Synonyms (25)

Synonym
NCGC00165796-01
fti-276
n-[2-phenyl-4-n[2(r)-amino-3-mercaptopropylamino benzoyl]-methionine, tfa
CHEMBL54044 ,
(2s)-2-[[4-[[(2r)-2-amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid
bdbm50067584
2-{[5-((r)-2-amino-3-mercapto-propylamino)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyric acid
2-{[5-(2-amino-3-mercapto-propylamino)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyric acid
(s)-2-{[5-((r)-2-amino-3-mercapto-propylamino)-biphenyl-2-carbonyl]-amino}-4-methylsulfanyl-butyric acid
fti276
BRD-K75532464-001-01-4
gtpl6531
fti 276
SCHEMBL2722114
170006-72-1
AKOS027324207
CHEBI:94119
HY-15873
CS-0009428
(s)-2-(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoic acid.
Q27077751
(s)-2-(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-ylcarboxamido)-4-(methylthio)butanoic acid
(5-(((r)-2-amino-3-mercaptopropyl)amino)-[1,1'-biphenyl]-2-carbonyl)-l-methionine
DTXSID501124981
n-[[5-[[(2r)-2-amino-3-mercaptopropyl]amino][1,1'-biphenyl]-2-yl]carbonyl]-l-methionine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Potent and orally bioavailable nonthiol-containing inhibitors of protein farnesyltransferase are described."( Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase.
Augeri, DJ; Cherian, S; Cohen, J; Dickman, D; Ding, H; Janowick, D; Kalvin, D; Kovar, P; Larsen, J; Lee, J; Ng, SC; Rosenberg, SH; Saeed, B; Sham, H; Sullivan, G; Tahir, S; Warner, R; Zhang, H, 1999
)
0.3

Dosage Studied

ExcerptRelevanceReference
" In vitro, all compounds demonstrated growth inhibition at a dose-response manner; however, manumycin, gliotoxin, and DHEA demonstrated an initial increase in growth rate at lower doses."( Chemopreventive efficacy of promising farnesyltransferase inhibitors.
Crist, KA; Hara, M; Lantry, LE; Lubet, RA; Wang, Y; You, M; Zeeck, A; Zhang, Z, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methionine derivativeAn amino acid derivative resulting from reaction of methionine at the amino group or the carboxy group, or from the replacement of any hydrogen of methionine by a heteroatom. The definition normally excludes peptides containing methionine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.25890.004023.8416100.0000AID485290
phosphopantetheinyl transferaseBacillus subtilisPotency44.66840.141337.9142100.0000AID1490
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency7.94330.354828.065989.1251AID504847
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein farnesyltransferase subunit betaSaccharomyces cerevisiae S288CIC50 (µMol)0.00080.00080.00080.0008AID1803146
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)IC50 (µMol)0.00050.00050.28191.1000AID73101
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaSaccharomyces cerevisiae S288CIC50 (µMol)0.00080.00080.00080.0008AID1803146
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)IC50 (µMol)0.00670.00050.471610.0000AID1121276; AID1121277; AID1313127; AID1371353; AID164306; AID164327; AID1803147; AID568205; AID71317; AID71327; AID72946; AID73125; AID73275; AID73400
Protein farnesyltransferase subunit betaBos taurus (cattle)IC50 (µMol)0.00050.00050.11831.1000AID73101
Protein farnesyltransferase subunit betaHomo sapiens (human)IC50 (µMol)0.00330.00050.21772.5000AID1121277; AID1313127; AID1371353; AID164306; AID164327; AID1803147; AID568205; AID71317; AID71327; AID72946; AID73125; AID73275; AID73400
Geranylgeranyl transferase type-1 subunit betaHomo sapiens (human)IC50 (µMol)0.05000.00732.364210.0000AID1121276
Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaMus musculus (house mouse)IC50 (µMol)1.00001.00001.00001.0000AID143949
Protein farnesyltransferase subunit betaMus musculus (house mouse)IC50 (µMol)1.00001.00001.00001.0000AID143949
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)
transforming growth factor beta receptor signaling pathwayProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of Rac protein signal transductionProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of tubulin deacetylationProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of deacetylase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
positive regulation of skeletal muscle acetylcholine-gated channel clusteringProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
lipid metabolic processProtein farnesyltransferase subunit betaBos taurus (cattle)
protein farnesylationProtein farnesyltransferase subunit betaBos taurus (cattle)
lipid metabolic processProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesylationProtein farnesyltransferase subunit betaHomo sapiens (human)
protein geranylgeranylationGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
Rab geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
receptor tyrosine kinase bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
alpha-tubulin bindingProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
molecular adaptor activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaBos taurus (cattle)
zinc ion bindingProtein farnesyltransferase subunit betaBos taurus (cattle)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase activityProtein farnesyltransferase subunit betaHomo sapiens (human)
protein bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
zinc ion bindingProtein farnesyltransferase subunit betaHomo sapiens (human)
protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
protein bindingGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
zinc ion bindingGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase activityGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaBos taurus (cattle)
cytosolProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
plasma membraneProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
cytoplasmProtein farnesyltransferase/geranylgeranyltransferase type-1 subunit alphaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaBos taurus (cattle)
cytosolProtein farnesyltransferase subunit betaHomo sapiens (human)
microtubule associated complexProtein farnesyltransferase subunit betaHomo sapiens (human)
protein farnesyltransferase complexProtein farnesyltransferase subunit betaHomo sapiens (human)
CAAX-protein geranylgeranyltransferase complexGeranylgeranyl transferase type-1 subunit betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (36)

Assay IDTitleYearJournalArticle
AID215858Effective dose required to inhibit the growth of Trypanosoma brucei2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID225440Inhibition of Plasmodium falciparum 3D7 infected red blood cells2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.
AID73400Inhibitory concentration against farnesyltransferase was determined2004Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8
Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
AID144118Inhibition of Ha-Ras processing in NIH3T3 Ras transformed cells.1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
AID1121275Selectivity ratio of IC50 for human recombinant FTase to IC50 for human GGTase 1 in human Burkitt lymphoma (Daudi) cell supernatant2013MedChemComm, Mar, Volume: 4, Issue:3
Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
AID73125Inhibitory activity against farnesyltransferase (FT) using SPA assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Potent inhibitors of protein farnesyltransferase: heteroarenes as cysteine replacements.
AID164361Inhibition of kinase activity of Raf/MEK/ERK kinase cascade in ELISA (Not tested)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID616637Inhibition of rat recombinant FTase using Dansyl-Gly-Cys-Val-Leu-Ser-OH peptide and farnesyl-pyrophosphate substrates measured every 15 seconds for 5 mins by fluorescent assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.
AID164306Inhibition of Trypanosoma brucei protein farnesyltransferase2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID1487407Inhibition of Trypanosoma brucei recombinant farnesyltransferase using dansyl peptide containing GCAIM as substrate in presence of farnesyl pyrophosphate after 15 mins by fluorescence assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Structure-activity relationship studies on thiaplidiaquinones A and B as novel inhibitors of Plasmodium falciparum and farnesyltransferase.
AID71317Inhibition of mammalian Farnesyltransferase2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.
AID72946In vitro inhibitory activity was evaluated against farnesyltransferase (FTase)1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase.
AID144250Inhibition of H-ras processing in subconfluent H-Ras-transformed NIH3T3 cells1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Potent inhibitors of protein farnesyltransferase: heteroarenes as cysteine replacements.
AID164327Inhibition of mammalian protein farnesyltransferase2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID102170Inhibition of human adenocarcinoma cell line LoVo proliferation2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID1313127Inhibition of human recombinant farnesyltransferase using farnesylpyrophosphate and dansyl-GCVLS as substrate measured for 15 mins by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation.
AID225442Percent growth inhibition of Plasmodium falciparum 3D7 in red blood cells at 20 uM; Not determined2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.
AID73101In vitro inhibition of farnesyltransferase from bovine brain1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
AID215880Effective dose required to inhibit the growth of Trypanosoma brucei rhodesiense2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID1313126Inhibition of human recombinant farnesyltransferase using farnesylpyrophosphate and dansyl-GCVLS as substrate at 100 uM measured for 15 mins by fluorescence assay2016Bioorganic & medicinal chemistry letters, 08-01, Volume: 26, Issue:15
New indolizine-chalcones as potent inhibitors of human farnesyltransferase: Design, synthesis and biological evaluation.
AID71327Inhibition of [3H]FPP incorporation into Ha-ras protein by Farnesyltransferase2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
3-Aryl-4-aryloyl-1-(1H-imidazol-5-yl)methylpyrrole, a novel class of farnesyltransferase inhibitors.
AID126783Inhibition of Mitogen-activated protein kinase (MAPK)phosphorylation by activated MEK-1 (Not tested)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID568205Inhibition of human FTase after 15 mins by fluorimetric analysis2011Bioorganic & medicinal chemistry letters, Feb-15, Volume: 21, Issue:4
Chemical and biological explorations of the electrophilic reactivity of the bioactive marine natural product halenaquinone with biomimetic nucleophiles.
AID1121276Inhibition of human GGTase1 in human Burkitt lymphoma (Daudi) cell supernatant using [3H]geranylgeranyl2013MedChemComm, Mar, Volume: 4, Issue:3
Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
AID1487406Inhibition of recombinant human farnesyltransferase using dansyl-GCVLS as substrate in presence of farnesyl pyrophosphate after 15 mins by fluorescence assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
Structure-activity relationship studies on thiaplidiaquinones A and B as novel inhibitors of Plasmodium falciparum and farnesyltransferase.
AID1121277Inhibition of human recombinant FTase using [3H]farnesyldiphosphate2013MedChemComm, Mar, Volume: 4, Issue:3
Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.
AID73275Inhibition of farnesyltransferase from human Burkitt lymphoma (Daudi) cells2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold.
AID143949Inhibition of mammalian H-Ras processing in NIH 3T3 cells2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.
AID45091Inhibition of human adenocarcinoma cell line Caco-2 proliferation2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID126619Inhibition of MEK1 phosphorylation by activated human recombinant Raf (Not tested)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1).
AID1371353Inhibition of FTase isolated from human Burkitt's lymphoma cells assessed as decrease in transfer of [3H]farnesyl from [3H]farnesyl PPi to H-Ras-CVLS2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
AID3339Effective dose against murine 3T3 fibroblasts cells2004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents.
AID1803147Human FTase Assay from Article 10.3109/14756366.2011.643302: \\New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.\\2013Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 28, Issue:1
New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.
AID1803146Yeast FTase Assay from Article 10.3109/14756366.2011.643302: \\New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.\\2013Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 28, Issue:1
New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.
AID1803148T. brucei FTase Assay from Article 10.3109/14756366.2011.643302: \\New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.\\2013Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 28, Issue:1
New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.
AID1346248Human farnesyltransferase, CAAX box, beta (2.5.1.58 Protein farnesyltransferase)1995The Journal of biological chemistry, Nov-10, Volume: 270, Issue:45
Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (13.79)18.2507
2000's12 (41.38)29.6817
2010's13 (44.83)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.41 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]